Table 2 VLP-based vaccines against different cancers
VLP type | Cancer type | Antigen | Clinical phase | References |
|---|---|---|---|---|
MS2 | Cervical | L2 | Preclinical | [192] |
AP205 | Cervical (and placental malaria) | HPV RG1 epitope (and VAR2CSA PM antigen) | Preclinical | [193] |
AP205 | Breast | HER-2 | Preclinical | [190] |
MS2 | Breast | xCT | Preclinical | [200] |
MS2 | Breast | xCT | Preclinical | [201] |
SHIV | Pancreatic | hMSLN | Preclinical | [202] |
SIV | Pancreatic | mTrop2 | Preclinical | [204] |
eCPMV | Melanoma | Empty | Preclinical | [204] |
Cucumber mosaic VLPs (CMV) | Melanoma | LCMV-gp33 | Preclinical | [208] |
Bacteriophage Qβ | Melanoma | PMEL17, MTC-1, Calpastatin, ZFP518, TRP-2, Caveolin2, Cpsf3l and Kifl8b | Preclinical | [208] |